Theoretical Cost-Effectiveness of PCSK9 Inhibitors in Stroke Due to Intracranial Atherosclerosis - Report - MDSpire

Theoretical Cost-Effectiveness of PCSK9 Inhibitors in Stroke Due to Intracranial Atherosclerosis

  • By

  • Caroline Kellogg

  • Elena Badillo Goicoechea

  • David D. Kim

  • Shadi Yaghi

  • Seemant Chaturvedi

  • Rachel Mehendale

  • Karen Orjuela

  • Tareq Kass-Hout

  • Rami Z. Morsi

  • Jacqueline Morales

  • Eesha Singh

  • Aditya Jhaveri

  • Shyam Prabhakaran

  • Matthew M. Smith

  • James R. Brorson

  • Samiksha Golani

  • Sofia Mazuera

  • Rachael Kang

  • Ali Eltatawy

  • Jessica Pillajo

  • James E. Siegler

  • May 5, 2026

  • 0 min

Share

Clinical Report: Evaluating the Cost-Effectiveness of PCSK9 Inhibitors for Managing Stroke

Overview

{'willingness_to_pay': 'Clarify the specific thresholds and their implications.'}

Background

{'statistics': 'Add specific prevalence statistics for dyslipidemia.'}

Data Highlights

{'remove': 'Delete the statement about lack of numerical data.'}

Key Findings

{'support': 'Ensure all claims are backed by the source.'}

Clinical Implications

{'research': 'Highlight the need for further validation of cost-effectiveness.'}

Conclusion

{'research': 'Specify areas needing further investigation.'}

References

  1. European Journal of Preventive Cardiology, 2025 -- Impact of PCSK9 inhibitors on lipoprotein(a) levels: a multi-centre study
  2. Clinical Research in Cardiology, 2026 -- Short-term lesion-level impact of extensive LDL-C reduction with statins and PCSK9 inhibitors: a pre-specified subgroup analysis of the randomized FITTER trial
  3. conexiant, 2025 -- ApoB Goal Cost-Effective in Primary Prevention
  4. Clinical Research in Cardiology, 2016 -- Targeted Objectives for Reducing LDL-C Levels Based on Evidence
  5. AHA/ASA Stroke Secondary Prevention Guideline: Key Points - American College of Cardiology, 2021
  6. Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease: A Network Meta-analysis - PubMed, 2023
  7. HIGHLIGHTS OF PRESCRIBING INFORMATION, 2025
  8. AHA/ASA Stroke Secondary Prevention Guideline: Key Points - American College of Cardiology
  9. Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease: A Network Meta-analysis - PubMed
  10. HIGHLIGHTS OF PRESCRIBING INFORMATION

Original Source(s)

Theoretical Cost-Effectiveness of PCSK9 Inhibitors in Stroke Due to Intracranial Atherosclerosis

  • by Caroline Kellogg, Elena Badillo Goicoechea, David D. Kim, Shadi Yaghi, Seemant Chaturvedi, Rachel Mehendale, Karen Orjuela, Tareq Kass-Hout, Rami Z. Morsi, Jacqueline Morales, Eesha Singh, Aditya Jhaveri, Shyam Prabhakaran, Matthew M. Smith, James R. Brorson, Samiksha Golani, Sofia Mazuera, Rachael Kang, Ali Eltatawy, Jessica Pillajo, James E. Siegler

  • May 5, 2026

Related Content

Vardenafil in the multidisciplinary management of erectile dysfunction: a narrative review on multidimensional outcomes and clinical integration

May-Thurner Syndrome as a Hidden Etiology of Ischemic Stroke in Young Adults

NVMC receives Get With The Guidelines Target Stroke Honor Roll Elite Plus Gold Plus Quality Achievement Award

Sentara Northern Virginia Medical Center has received the American Heart Association/American Stroke Association’s Get With The Guidelines® Target: Stroke Honor Roll Elite Plus Gold Plus Quality Achievement Award.